Otsuka Holdings Co 4578.T · JPY
Health Care · Pharmaceuticals · Tokyo Stock Exchange · 🇯🇵 Japan
11,965
+3.28%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Otsuka Holdings Co
Its shares trade on Tokyo Stock Exchange under the ticker 4578.T. It has been listed since 15 December 2010. In the fiscal year to 31 December 2025, it reported revenue of ¥2.47trn and net income of ¥363.15bn. At that date it held total assets of ¥4.20trn and shareholders' equity of ¥3.03trn.
Otsuka Holdings Co., Ltd. engages in the manufacture and sale of pharmaceuticals and nutritional supplements. The company is headquartered in Chiyoda-Ku, Tokyo-To. The company went IPO on 2010-12-15. The firm operates through four business segments. The Medical-related segment is engaged in the sale of ethical drugs, and the research development and export of therapeutic drugs. The Nutraceuticals-related segment is engaged in the manufacture, purchase and sale of nutraceuticals-related products, such as functional food and dietary supplements. The Consumer-related segment is engaged in the manufacture and sale of consumer products and mineral water. The Others segment is engaged in the manufacture and sale of chemical products, the manufacture, sale and import of measuring equipment, and the manufacture of synthetic resin molding products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Dec 2010
- Employees
- 32,992
- Website
- otsuka.com/jp ↗
Leadership
Pay as last reported
- Mr. Ichiro OtsukaChairman of the Board, Representative Director, since 2008¥171.0m
- Mr. Makoto InouePresident, Chief Executive Officer, President of Subsidiary, Representative Director, since 2020¥124.0m
- Ms. Yuko MakinoChief Financial Officer, Director, since 2016¥89.0m
- Mr. Tatsuo HiguchiChairman of Subsidiary, Director, since 2008¥214.0m
- Mr. Masayuki KobayashiChairman & President of Subsidiaries, Director, since 2017¥64.0m
- Mr. Shuichi TakagiPresident of Subsidiary, Director, since 2019¥58.0m
- Ms. Noriko TojoPresident of Subsidiary, Director, since 2018¥61.0m
- Mr. Yoshiro MatsuoVice President, Representative Director, since 2008¥125.0m
- Mr. Chiaki SakuraiSenior Managing Executive Officer, Chief Director of Nutraceuticals Business Global Strategy and Planning
- Mr. Tomohiro EmuraManaging Executive Officer
- Mr. Manabu KawataManaging Executive Officer
- Mr. Keiso YamasakiManaging Executive Officer, Director of Business Planning
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 97
- Environment
- 99
- Social
- 99
- Governance
- 92
- Direct emissions (scope 1)
- 327,309 t
- Energy emissions (scope 2)
- 195,362 t
- Value chain emissions (scope 3)
- 995,597 t
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Otsuka Holdings Co Ltd has maintained a strong financial performance, which allows it to invest in research and development, expand its product portfolio, and pursue growth opportunities.
- With a diverse range of products in areas such as pharmaceuticals, nutraceuticals, and beverages, Otsuka Holdings Co Ltd is well-positioned in multiple markets. This diversification helps mitigate risks by reducing dependence on any single product or market.
- Otsuka Holdings Co Ltd has a strong commitment to research and development, enabling it to innovate and bring new products to market. The company's R&D capabilities contribute to its ability to address unmet medical needs and maintain a competitive edge.
Weaknesses
- Otsuka Holdings Co Ltd heavily relies on key markets for a significant portion of its revenue. Any adverse changes in these markets, such as regulatory hurdles or economic downturns, could have a negative impact on the company's financial performance.
- While Otsuka Holdings Co Ltd has a strong presence in its home market, Japan, its global reach is relatively limited compared to some of its competitors. This could restrict its growth potential and make it vulnerable to fluctuations in regional markets.
- As a company operating in the healthcare industry, Otsuka Holdings Co Ltd faces the inherent risk of product recalls. Any product quality issues or safety concerns could damage the company's reputation and financial performance.
Opportunities
- Otsuka Holdings Co Ltd can capitalize on the growing demand for healthcare products and services in emerging markets. By expanding its operations and distribution networks in these markets, the company can tap into new sources of revenue and achieve long-term growth.
- Advancements in technology, such as digital healthcare solutions and artificial intelligence, present opportunities for Otsuka Holdings Co Ltd to develop innovative products and improve patient care. Investing in these areas can enhance the company's competitive position.
- Forming strategic partnerships and collaborations with other companies or research institutions can provide Otsuka Holdings Co Ltd with access to new technologies, expertise, and markets. Such collaborations can foster innovation and support the company's growth strategy.
Threats
- The healthcare industry is highly competitive, with many players vying for market share. Otsuka Holdings Co Ltd faces competition from both domestic and international companies, which could impact its market position and profitability.
- Regulatory requirements and compliance pose challenges to Otsuka Holdings Co Ltd, particularly in the pharmaceutical sector. Changes in regulations or failure to meet compliance standards could result in delays, increased costs, or even product restrictions.
- Global economic uncertainties, market volatility, and currency fluctuations can affect Otsuka Holdings Co Ltd's financial performance and profitability, especially when it comes to operating in international markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.